Drug Type Virus-like particle vaccine, Prophylactic vaccine, Multivalent vaccine + [1] |
Synonyms Cervical cancer vaccine Shanghai Zerun Biotechnology, HPV16/18 vaccine Shanghai Zerun Biotechnology, HPV2 vaccine + [7] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (24 Mar 2022), |
RegulationPriority Review (CN) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Human Papillomavirus-Related Cervical Adenocarcinoma In Situ | ID | 10 Oct 2024 | |
Human Papillomavirus-Related Cervical Intraepithelial Neoplasia | ID | 10 Oct 2024 | |
Human Papillomavirus-Related Cervical Carcinoma | CN | 24 Mar 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Human Papillomavirus Infection | NDA/BLA | CN | 01 Jul 2020 | |
HPV16 Infection | Phase 2 | CN | 26 Sep 2013 | |
Uterine Cervical Cancer | Phase 2 | CN | 26 Sep 2013 | |
Uterine Cervical Dysplasia | Phase 2 | CN | 26 Sep 2013 |